You are here

Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43NS084575-01A1
Agency Tracking Number: R43NS084575
Amount: $203,226.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NINDS
Solicitation Number: PA13-234
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
349 Eddy Street
PROVIDENCE, RI 02903-
United States
DUNS: 140315248
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 YOW-PIN LIM
 (401) 301-2046
 yplim@protherabiologics.com
Business Contact
 YOW LIM
Phone: (401) 301-2046
Email: yplim@protherabiologics.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory response contributing to neuronal cell death. Unfortunately, current treatment and prevention strategies in newborns are lacking and inadequate. There are no currently available therapies to prevent/treat and/or attenuate brain damage in premature infants and the only available therapeutic intervention for full term infants is hypothermia, which is only partially protective. Inter-alpha Inhibitor Proteins (IAIP) are naturally derived molecules that have been shown to play an important role in modulating inflammatory response by down-regulating pro-inflammatory cytokines in several experimental models of newborn and a

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government